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Directed evolution of Bacillus subtilis Lipase A by enantiomeric 
phosphonate inhibitors: crystal structures and phage display selection 
Phage display can be used as a protein engineering tool for the selection of proteins 
with desirable binding properties from a library of mutants. Here, we describe the 
application of this method for the directed evolution of Bacillus subtilis lipase A, an 
enzyme that has marked properties for the preparation of the pharmaceutically 
relevant chiral compound 1,2-O-isopropylidene-sn-glycerol (IPG). PCR mutagenesis 
using spiked oligonucleotides was employed for saturation mutagenesis of a stretch of 
amino acids near the active site. After expression of these mutants on bacteriophages, 
dual selection on S-(+)- and R-(-)-IPG stereoisomers covalently coupled to 
enantiomeric phosphonate suicide inhibitors (SIRAN Sc and Rc inhibitors, 
respectively) was used for the isolation of variants with an inverted enantioselectivity. 
The mutants were further characterised by determination of their Michaelis-Menten 
parameters. The 3D structures of the Sc and Rc inhibitor – lipase complexes were 
determined to provide structural insight into the mechanism of enantioselectivity of 
the enzyme. In conclusion, we have used phage display as a fast and reproducible 





In pharmacotherapy, the use of enantiopure drugs is often associated with improved 
potency and selectivity of the compound. In addition, adverse side effects resulting from the 
‘wrong’ enantiomer are eliminated. As such, the production and isolation of pure 
enantiomers has become an important process in pharmaceutical and chemical industries. In 
particular, bacterial enzymes, such as lipases, have been used for the production of 
enantiopure intermediates and drugs, since they are capable of enantioselective hydrolysis 
and esterification 40,40,213-215. Moreover, in the past decades, protein engineering has opened 
the possibility to tailor enzymes with specific properties and interesting practical 
applications 216. 
 
We chose to study the chiral intermediate 1,2-O-isopropylidene-sn-glycerol (IPG), since 
IPG is a starting compound in the chemical synthesis of ß-adrenoceptor antagonists. Lipase 
A of Bacillus subtilis 168 (LipA) is of particular interest for the production of enantiopure 
IPG as it shows some advantageous characteristics compared to other lipases. It has a 
relatively low molecular mass (181 amino acids, 19 kDa) and it can be well expressed and 
engineered in Escherichia coli and B. subtilis, since it does not require specific chaperones 
for proper folding and secretion. Furthermore, this enzyme represents one of the few 
examples of a lipase that does not show interfacial activation in the presence of oil-water 
interfaces 35,36,172. Finally, the crystal structure of B. subtilis LipA has been elucidated 27. 
Like other lipases, the fold of B. subtilis LipA resembles the core of enzymes of the α/ß 















IPG acetate 18.7 34.6 ± 0.2 73.2 ± 1.9 9.2 ± 0.8 (-)-IPG 
IPG butyrate 2.25 31.9 ± 2.7 20.3 ± 1.6 2.2 ± 0.0 (-)-IPG 
IPG carpylate 0.6 31.7 ± 1.8 42.9 ± 5.7 3.1 ± 0.6 (-)-IPG 
 
* E values are defined as the ability of the enzyme to distinguish between enantiomers  
  (E < 1 enantiopreference for (+)-IPG; E > 1 enantiopreference for (-)-IPG) 
 
present in the larger lipases, the B. subtilis LipA can be regarded as a minimal α/ß 
hydrolase fold enzyme.  
 
We have already established that purified LipA can hydrolyse acetate, butyrate and 
caprylate esters of IPG, although hardly any enantioselective preference was observed (ee 
ranging from 20.3% to 73.2% for (-)-IPG, table I). Therefore, our aim was to invert and 
improve the enantioselective hydrolysis by B. subtilis LipA of the enantiomer of interest, S-
(+)-IPG. We mutated residues 16 to 20 of the mature LipA with localised saturation PCR 
mutagenesis, as this region might be of particular interest for the enantioselective 
characteristics of this enzyme 27. Recently, it was demonstrated that LipA of B. subtilis can 
be functionally expressed as a fusion to the phage coat protein g3p 103. In this study, we 
evaluated for the first time the use of enantiomeric phosphonate suicide inhibitors for the 
selection of phage displayed LipA mutants with an inverted enantioselectivity. These 
phosphonates bind covalently to the active site serine of a lipase molecule, thus mimicking 
the conformation of the first transition state in ester hydrolysis (scheme 1) 103,217. Finally, 
the 3D structures of both enantiomers of the IPG phosphonate inhibitor bound in the lipase 
active site were determined to provide a structural explanation for the enantioselectivity of 









Transition state Structure of mimic  
 
Scheme 1: Schematic comparison of the structure of covalently bound IPG phosphonate inhibitor 
mimicking the tetrahedral transition state in the ester hydrolysis. 
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Experimental procedures 
Plasmids, bacterial strains and media 
E. coli TG-1 (supE, K12 ∆(lac-pro), thi, hsdD5/F’, traD36, proAB, laqIq, lacZ∆-M15), E. 
coli HB2151 (K12 ∆(lac-pro), ara, nalr, thi/F’, proAB, laqIq, lacZ∆-M15), helperphage 
M13KO7 and pCANTAB 5E were purchased from Pharmacia (Amersham Pharmacia 
Biotech, Uppsala, Sweden). 2xTY medium contained: Bactotrypton (1.6% w/v), Bacto 
yeast extract (1% w/v) and sodium chloride (0.5% w/v). As antibiotic agents ampicillin (100 
µg.mL-1) and kanamycin (50 µg.mL-1) (Duchefa Biochemie, Haarlem, The Netherlands) 
were used. 
 
Mutagenesis of the lipA gene 
The LipA encoding gene was cloned in the phagemid pCANTAB 5E, downstream of a 
modified g3p signal sequence, as described previously 103. To introduce an ApaLI 
restriction site in the lipA gene, a silent mutation at base pair position 27 of the lipA gene 
was made using the oligonucleotides lipapaLI (Life Technologies, UK):  
5’-CAGTCGTTATGGTGCACGGTATTGGAGGGGC-3’ (ApaLI) and lipArev:  
5’-TCAAGGTTTTGTTGCGGCCGCCTTCGTATTCTGGCC -3’ (Eco52I). Restriction 
sites are indicated in bold italics. To construct the mutant library, the following primer was 
used (Eurosequence, Groningen, The Netherlands): 00B468a:  
5’-ATGGTGCACGGTATTGGAGGGGCA576557665555878GGAATTAAGAGC-3’ 
(ApaLI; 5 = 80% T; 6 = 80% A; 7 = 80% C; 8 = 80% G; the remaining 20% is an equal 
mixture of the other three bases). Recombinant DNA procedures were carried out as 
described by Sambrook et al 176. Plasmid DNA was prepared according to Birnboim & 
Doly 177. DNA purification was performed using the Qiaquick Gel Extraction kit (Qiagen, 
Hilden, Germany). The library was amplified from the chromosomal DNA of B. subtilis 
168 using Pfu DNA polymerase (Stratagene, La Jolla, CA, USA). The gene fragment was 
digested with ApaLI and Eco52I (Pharmacia), and cloned in E. coli TG-1 into the ApaLI 
and Eco52I sites of the phagemid pCANTABLip-CH 103. Prior to phage display, the 
constructs were sequenced to assess the mutation ratio. The LipA F17DF19W mutant was 
constructed using the oligonucleotide F17DF19W 5’-
TCCAGTCGTTATGGTGCACGGTATTGGAGGGGCATCAGACAATTGGGCGGGAA
TTAAGAG-3’ (ApaLI) and lipArev. The gene fragment was digested with ApaLI and 




Phages were rescued as described by Dröge et al 103. In short, helperphages were added to 
exponential phase growing E. coli TG-1 cells (i.e. phage-to-bacterium ratio 30:1), followed 
by 16 h of growth at 28ºC in 2xTY medium. Phages were precipitated by addition of 
polyethylene glycol (40% w/v) in NaCl (0.6 M). After centrifugation, the phages were 
resuspended in Tris HCl buffer (10 mM, pH 7.4) containing ethylene diamine tetraacetic 
acid (EDTA, 1 mM), and passed through a 0.45 µm filter (Millipore, Bedford, MA, USA.). 
The number of phage particles was determined by mixing 150 µL of a diluted phage 
suspension (102 – 108-fold) with 150 µL exponential-phase growing E. coli TG-1 cells. 
After plating and overnight growth, the number of infective phages was counted.  
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Dual selection using enantiomeric phosphonate inhibitors 
Enantiomeric phosphonate inhibitors (SIRAN Sc and Rc inhibitors) were synthesised 
according to Reetz et al 217. All selections were in assay buffer (50 mM phosphate buffer, 
pH 8, 0.36% v/v Triton X100 and 0.1% w/v gum arabic) at room temperature. Triton X100 
was used to reduce the aspecific interaction. For selection round 1, 10 mg of the SIRAN Sc 
inhibitor (loading 10 mmol inhibitor.g-1 SIRAN) was washed twice for 10 minutes using 
500 µL assay buffer. Note that the inhibitor does not dissolve in this solution. The reaction 
mixture was vertically rotated during incubation. Subsequently, lipase expressing phages 
were added and allowed to react for 15 minutes. Then, the supernatant was removed and the 
inhibitor was washed 8 times for 10 minutes to remove all non-bound and aspecifically 
bound phages. Afterwards, collagenase A (0.1% w/v, Roche, Mannheim, Germany) was 
added (1 hour incubation at 37ºC) to elute the bound phages. The total number of phages in 
each fraction was determined by phage counting. The phagemids were propagated by 
mixing the phages with exponential phase growing E. coli TG-1 cells (i.e. phage-to-
bacterium ratio 30:1). After overnight growth, phages expressing lipase can be produced as 
described above.  
Subsequently, 10 mg of the SIRAN Rc and Sc inhibitors were washed separately. Lipase 
expressing phages of round 1 were added to the SIRAN Rc inhibitor and allowed to react 
for 15 minutes (selection round 2). Then, the supernatant was isolated and incubated on the 
SIRAN Sc inhibitor. After 5 minutes, the supernatant was removed and the inhibitor was 
washed 8 times for 10 minutes. Afterwards, collagenase A (0.1% w/v) was added to elute 
the bound phages. The total number of phages in each fraction was determined by phage 
counting. The phagemids were propagated using E. coli TG-1 cells and, after overnight 
growth, lipase expressing phages were produced as described above. This procedure was 
repeated another two times (selection round 3 and 4). After the fourth round of selection, 
the eluted phages were incubated with exponential phase growing E. coli HB2151 for 
isolation of lipase from the periplasm. 
 
Isolation of the periplasmic fraction 
E. coli HB2151 was grown in 50 mL tubes containing 10 mL 2xTY medium, ampicillin 
and of isopropyl-β-D-galactopyranoside (IPTG, 1 mM). The tubes were incubated at 37ºC at 
250 rpm for 16 h. The OD600 was recorded and the cells were harvested and resuspended 
in Tris HCl buffer (10 mM, pH 7.4). After centrifugation, the cells were resuspended in 200 
µL buffer containing Tris HCl, (10 mM, pH 8.0), sucrose (25% w/v), EDTA (2 mM) and 
lysozyme (0.5 mg.mL-1, Sigma-Aldrich, Steinheim, Germany). After incubation on ice for 
20 min, 50 µL buffer containing Tris HCl (10 mM, pH 8.0), sucrose (20% w/v) and MgCl2 
(125 mM) was added. The suspension was centrifuged and the supernatant, containing the 
periplasmic fraction, was isolated and used as enzyme solution in the IPG ester assay. The 
protein content of this fraction was determined by performing a Bradford assay in triplicate 
using bovine serum albumin (BSA) as a standard (Pierce, Rockford, Illinois, USA). 
 
1,2-O-isopropylidene-sn-glycerol ester assay  
Periplasmic fractions were diluted with MOPS buffer (0.07 M, pH 7.5), containing BSA 
(0.2% w/v), to a final volume of 100 µL. References were diluted correspondingly but 
contained no enzyme solution. The esters of IPG (1 mM) were dissolved in 10 mL MOPS 
buffer (0.07 M, pH 7.5), containing Tween 80 (14.3% w/v), and diluted to 50 mL with 
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MOPS buffer (0.07 M, pH 7.5). 500 µL substrate solution was added to the enzyme solution 
and the final mixture was incubated in a water bath at 32°C. After incubation, 500 µL 
saturated NaCl solution and 10 µL internal standard solution (racemic 3-hexene-1-ol, 5 
mg.mL-1 assay buffer) was added to the sample solution and the aqueous solution was 
extracted twice with 1 mL ethyl acetate. GC analysis was performed as described by Dröge 
et al 180. One unit (U) is defined as the amount of enzyme that hydrolyses 1 µmol IPG ester 
per minute. Enantiomeric excesses, ee, were calculated according to Chen et al and were 
defined as the ability of the enzyme to distinguish between enantiomers 181. All data were 
expressed as mean ± SEM. The statistical significance of differences was tested at a 
significance level of p<0.05 using a two-tailed Student's t-test.  
 
Enzyme purification and characterisation 
E. coli HB2151 was grown for 16 h at 37 °C in 1 L of 2xTY medium supplemented with  
ampicillin (100 µg.mL-1) and IPTG (1 mM). The periplasmic fraction was isolated as 
described above. Histidine tagged LipA was purified using an immobilised metal affinity 
chromatography (IMAC) resin (Talon, Clontech, Palo Alto, CA, USA). The protein was 
eluted with a linear gradient of imidazole (0.5 M in 10 mM Tris HCl, pH 7, containing 0.2 M 
NaCl). LipA N18I was purified as described by Lesuisse et al 36. Kinetic parameters were 
obtained by fitting the experimental data from Eadie-Hofstee plots. The mean and SEM 
values of four measurements were calculated. The kcat was calculated using the theoretical 
molecular mass of the his-tagged enzyme, 21 kDa.  
 
Binding of Rc or Sc inhibitors to crystallised lipase A 
Crystals were grown by vapour diffusion in hanging drops, which contained 3 µL B. 
subtilis LipA solution (6 mg.mL-1) and 3 µL reservoir solution (35% PEG4000, 0.1 M 
ethanolamine, pH 10.0, 20 mM Na2SO4 and 3 mM CdCl2) 27. The crystals were transferred 
to a 10 µL sitting drop with PEG4000 (45%), ethanol amine (0.1 M, pH 10.0), and Na2SO4 
(20 mM) in equilibrium with the same solution. The pH was lowered stepwise per 15 
minutes to pH 7.5 by removing most of the liquid surrounding the crystal followed by the 
addition of a similar solution of 0.5 unit lower pH. At pH 8.5 the buffer was replaced by 
triethanol amine (100 mM) as an additional step. Finally, the washing at pH 7.5 was done 
twice. To the final 10 µL drop, 1 µL of the phosphonate inhibitor (either Rc or Sc) was 
added. These phosphonate inhibitors form small oil drops on the surface of the drops 
containing the crystals. After 65 hours the crystals were flash frozen in liquid nitrogen and 
stored until data collection.  
 
X-ray data collection and refinement 
The data collection statistics are given in table II. The data were processed and scaled using 
DENZO and SCALEPACK 218. Reduction to structure factor amplitudes was performed 
with TRUNCATE 219. The B. subtilis LipA structure (PDB code 1I6W) was rigid body 
refined with CNS with both molecules in the asymmetric unit as separate bodies, without 
water molecules and Cd2+ ion 220. One round of simulated annealing was performed and the 
electron density at the active site was inspected. In both cases (Rc and Sc inhibitor), both 
molecules in the asymmetric unit clearly showed additional density extending from S77 
(PDB code 1R4Z and 1R5O, for the Rc and Sc inhibitor, respectively). The electron density 
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also showed a change of conformation of residues 10 to 15 in molecule B. The phosphonate 
inhibitors were built in the electron density and the loop of residues 10 to 15 in molecule B 
was rebuilt to fit the electron density. The structure was refined with CNS and water 
molecules were added. The refinement statistics are listed in table II. The solvent accessible 
surfaces were calculated using AREAIMOL from the CCP4 package 220,221. 
 
Table II: Data collection and refinement statistics. 
 
Data collection Rc inhibitor Sc inhibitor 
Beamline ESRF, ID14-2 ESRF, ID14-2 
Resolution (Å) 40-1.80 100-1.45 
Space group P212121 P212121 
a (Å), b (Å), c (Å) 39.49, 83.32, 94.64 39.59, 83.59, 95.08 
Number of reflections 166133 347481 
Number of unique reflections 26465 48857 
Completeness (%) 88.4 85.6 
Completeness last shell (%) 56.2 35.4 
Rmerge (%) 5.5 4.2 
Rmerge last shell (%) 21.1 30.5 
I/sigma 19.4 27.3 
I/sigma last shell 3.8 2.2 
Refinement statistics 
R-factor (%) 17.7 19.6 
Free R-factor (%) 21.0 21.6 
R.m.s. deviation from ideality 
Bond lengths (Å) 0.0047 0.0047 
Bond angles (˚) 1.19 1.23 
 
 
Results and discussion 
Construction of the mutant library 
The LipA encoding gene (Genbank accession number M74010) was cloned in phagemid 
pCANTAB 5E as described previously 103. An ApaLI restriction site was introduced at bp 
27 by a silent mutation. A spiked oligonucleotide was used to construct a saturated mutant 
library directed towards amino acids 16 to 20 of mature LipA (figure 1). These 
oligonucleotides resembled the lipA sequence for approximately 80%. Theoretically, this 
would yield a mutant library, which is composed mostly of single and double  




Figure 1: Schematic representation of the strcture of B. subtilis LipA. The structure shows a single 
compact domain that consists of six β-strands in a parallel β-sheet, surrounded by five α-helices. Two 
α-helices are located at one side of the β-sheet, whereas the other three are found at the opposite side 
(including a very small α-helix consisting of ony four amino acid residues). The catalytic triad 
residues serine, histidine and aspartate are labelled with S, H and D, respectively. The catalytic S77 
is positioned at a very sharp turn between a β-strand and an α-helix, the so-called nucleophile elbow. 
The letters N and C indicate the N- and C-termini, respectively. The amino acids 16-20, which have 
been subjected to saturation mutagenesis, are indicated in black. 
 
mutations. Sequence analysis of 24 clones revealed that 8% of the mutants had no amino 
acid mutation while the percentage of single, double, triple, quadruple mutated amino acids 
was 25%, 42%, 13%, 8%, respectively. Only 4% of the mutants contained five mutated 
amino acids. After transformation of E. coli TG-1, a mutant library consisting of 5 × 104 
colonies was obtained. This should be more than sufficient to saturate all possible single 
mutations at the amino acid level. E. coli TG-1, containing the mutant library, was infected 
with M13KO7 helperphages to produce phage particles containing the phagemid genome 
and a mixture of wild type and fusion g3p. The lipase fusion to g3p results from a partial 
suppression of the TAG stop codon in the host cells, E. coli TG-1. The number of phages 
with a possible lipase fusion protein was 8.3 × 1010, as determined by phage counting. 
 
Dual selection 
In order to develop a selection system for phage-bound LipA mutants, two transition state 
analogues were synthesised 217. These phosphonates bind covalently to the active site 
serine, thus mimicking the conformation of the first transition state of a substrate in the 
active site of a lipase molecule (scheme 1) 103,217. These two immobilised inhibitors 
contained the substrate analogue, 1,2-O-isopropylidene-sn-glycerol, respectively (+)-IPG or 
(-)-IPG (scheme 2A), a leaving group, p-nitrophenol, and a glass-bead matrix connected to 
the phosphonate moiety through a linker (scheme 2D). 
The dual selection procedure applied is schematically represented in figure 2. For the initial 































































S-(+)-IPG R-(-)-IPG Butyrate ester of S-(+)-IPG
= R-(+)-IPG butyrate
Butyrate ester of R-(-)-IPG
= S-(-)-IPG butyrate
O-[(S)-IPG] O-(p-nitrophenyl 6-hexenyl phosphonate
= phosphonate inhibitor of S-(+)-IPG = Sc inhibitor
O-[(R)-IPG] O-(p-nitrophenyl 6-hexenyl phosphonate
= phosphonate inhibitor of R-(-)-IPG = Rc inhibitor
SIRAN coupled phosphonate inhibitor of S-(+)-IPG
= SIRAN Sc inhibitor
SIRAN coupled phosphonate inhibitor of R-(-)-IPG
= SIRAN Rc inhibitor  
 
Scheme 2: A) Chemical structure of 1,2-O-isopropylidene-sn-glycerol (IPG). B) Chemical structure 
of the butyrate ester of IPG. C) Chemical structure of the soluble lipase inhibitors. D) Chemical 
structure of the SIRAN immobilised lipase suicide inhibitors. Note that the inhibitor is enantiopure at 
the chiral atom of the IPG molecule (Sc or Rc inhibitor) and racemic at the phosphorous atom 
(mixture of Rp and Sp inhibitor). The absolute configuration of IPG changes upon attachment to the 
phosphorous atom or upon ester bond formation. 
 
specifically isolate the phages that were able to bind to the SIRAN Sc inhibitor. For this 
purpose, 8.3 × 1010 phages were incubated with the SIRAN Sc phosphonate inhibitor and 
allowed to react for 15 minutes. After collagenase digestion, 1.4 × 106 phages containing 
the phagemid genome (as indicated by the presence of an ampicillin resistance marker) 
were obtained. Those phages were propagated by infection of exponential phase growing E. 
coli TG-1 cells. After overnight incubation, helperphages were added to produce a new 
phage pool containing the phagemid genome and a mixture of wild type and fusion g3p. 
Then, selection rounds 2, 3 and 4 were designed for the selection of enzymes with inverted 
enantioselectivity. We have previously established that phage-bound LipA reacts covalently 
with the SIRAN Rc and Sc inhibitors, revealing a half life of inactivation (t½ values) of 4.3 
± 0.2 (n=3) and 5.0 ± 0.1 (n=3) minutes for the SIRAN Rc and Sc inhibitor, respectively 103. 
1.0 × 1011 phages were incubated on the SIRAN Rc inhibitor and allowed to react for 15 
minutes (selection round 2). 
 
The supernatant, which contained the non-bound phages, was isolated and re-incubated on 
the SIRAN Sc inhibitor. After five minutes, the non-bound phages were discarded by 
removing the supernatant and the bound phages (1.8 × 106) were isolated by a collagenase  
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Table III: Dual selection experiment. The number of phase in each fraction was determined 
by phage counting. Note that the detection level of this method is 4 × 102 phages.ml-1.  
Amp: ampicillin resistance (phagemid genome); kana: kanamycin resistance 
(helperphages); n.d.: not determined. 
 
Number of phages Amp Kana Total 
Selection round 1 
 
8.0 × 1010 3.2 × 109 8.3 × 1010 
Selection round 1  
(collagenase elution) 
1.4 × 106 9.0 × 103 1.4 × 106 
Selection round 2 
 
1.0 × 1011 8.0 × 107 1.0 × 1011 
Selection round 2  
(collagenase elution) 
1.8 × 106 7.2 × 103 1.8 × 106 
Selection round 3 
 
1.0 × 1012 4.4 × 108 1.0 × 1012 
Selection round 3  
(collagenase elution) 
1.2 × 106 n.d. 1.2 × 106 
Selection round 4 
 
1.2 × 1012 8.0 × 109 1.2 × 1012 
Selection round 4  
(collagenase elution) 
2.0 × 106 4.0 × 104 2.0 × 106 
 
digestion. The phagemids were propagated using E. coli TG-1 cells and a new phage pool 
was produced. All results concerning the dual selection method are summarised in Table 
III. Additionally, we have determined the initial activity of each phage pool before each 
round of phage selection using the p-nitrophenyl caprylate assay as described previously 
103,217. This assay revealed rather similar activities for each phage pool (e.g. approximately 
0.4 U.mg-1). 
After two additional rounds of selection (selection round 3 and 4), the eluted phages were 
allowed to infect E. coli HB2151. As the TAG stop codon is not suppressed in this strain, 
soluble lipase will be secreted into the periplasm. 
 
Enzymatic activity 
The specific activity and enantioselectivity of 15 randomly chosen LipA mutants from 
selection round 4 towards IPG butyrate esters (scheme 2B) were determined and compared 
with wild type LipA (table III and figure 3). The periplasmic fraction was isolated to 
determine the enantioselectivity towards IPG butyrate, and the DNA was isolated for 
sequencing purposes. 11 mutants had enantioselectivities comparable to the wild type LipA, 
whereas one mutant was not enantioselective at all. Sequence analysis revealed that 8 of 
these 11 mutants contained a wild type amino acid sequence. In this respect, it should be 
mentioned that prior to the selection sequence analysis of 24 randomly chosen clones 
revealed only 2 wild type sequences. Therefore, the selection procedure has obviously 
enriched the phage pool with wild type sequence. Yet, 4 of the selected clones with a wild 





Figure 2: Schematic representation of the applied dual selection method. 
 
had in fact occurred. Most interestingly, 2 mutants had an inverted enantioselectivity (ee 
values of +32.9% and +35.3%). Sequence analysis revealed that both inverted mutants had 
the same sequence, namely LipA N18I. Therefore, the procedure selects in favour of the 
wild type LipA or LipA N18I sequence. 
 
Table IV: Enantioselective hydrolysis of racemic esters of IPG butyrate by periplasmic fractions of 










WT 26.7 ± 1.1 -33.3 ± 0.4 0.4 ± 0.0 (-)-IPG WT 
1 33.8 ± 1.0 -34.5 ± 0.7 0.4 ± 0.0 (-)-IPG WT 
2 44.0 ± 0.7 -24.2 ± 0.4 0.5 ± 0.0 (-)-IPG F17L 
3 41.8 ± 2.1 -33.0 ± 1.7 0.4 ± 0.0 (-)-IPG WT 
4 34.4 ± 2.6 -27.0 ± 2.9 0.5 ± 0.0 (-)-IPG WT 
5 26.1 ± 0.2 -33.9 ± 0.8 0.4 ± 0.1 (-)-IPG WT 
6 40.6 ± 0.3 -23.9 ± 1.7 0.5 ± 0.0 (-)-IPG F17IF19N 
7 30.9 ± 0.3 -38.1 ± 0.5 0.4 ± 0.0 (-)-IPG WT 
8 31.9 ± 0.3 +32.9 ± 0.8 2.3 ± 0.0*** (+)-IPG N18I 
9 32.7 ± 0.3 -35.1 ± 0.9 0.4 ± 0.0 (-)-IPG WT 
10 29.6 ± 1.3 +2.13 ± 0.2 1.0 ± 0.0*** (+)-IPG F17DF19. 
11 31.2 ± 0.5 -35.4 ± 0.6 0.4 ± 0.0 (-)-IPG WT 
12 29.1 ± 0.9 -35.5 ± 1.4 0.4 ± 0.0 (-)-IPG WT 
13 29.3 ± 1.8 -33.4 ± 0.7 0.4 ± 0.0 (-)-IPG F17YA20S 
14 41.7 ± 1.3 -19.0 ± 0.3 0.6 ± 0.0** (-)-IPG F19L 
15 33.1 ± 2.6 +35.3 ± 1.1 2.5 ± 0.1*** (+)-IPG N18I 
 
E values are defined as the ability of the enzyme to distinguish between enantiomers (E < 1 enantiopreference for 
(-)-IPG; E > 1 enantiopreference for (+)-IPG). Statistical significance of differences: ** p < 0.01, *** p < 0.001. 
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Figure 3: Enantioselective hydrolsys of racemic butyrate esters of IPG by LipA mutants. The assay 
conditions were described in the experimental procedures.  
Statistical significance of differences: ** p < 0.01; *** p < 0.001. 
 
Characterisation of the LipA N18I variant 
LipA and LipA N18I were purified and the Km and kcat values for the butyrate ester of IPG 
were determined (table V). Interestingly, the kcat value of LipA N18I on the butyrate ester 
of (-)-IPG was reduced (p < 0.05), but its Km value was not significantly lowered. As a 
consequence, LipA and LipA N18I do not have significant different catalytic efficiencies 
for butyrate ester of (-)-IPG (p > 0.05). In contrast, the Km value of LipA N18I towards the 
butyrate ester of (+)-IPG was significantly lowered (p < 0.01), which was reflected in a 
higher catalytic efficiency. Additionally, comparison of the enantiomeric excess ee towards 
(+)-IPG revealed an inversion of the enantioselectivity of LipA N18I compared to LipA (ee 
value for LipA N18I = +32.9% and +35.3%; ee value for LipA = -33.3%). 
 
Table V: Enzyme characteristics of the LipA N18I mutant (n=3). 
 
Enzyme Km (µM) 
butyrate 






















LipA 14.6 ± 1.9 0.6 ± 0.1 0.04 ± 0.00 3.5 ± 0.3 0.1 ± 0.0 0.03 ± 0.00 
LipA N18I 8.7 ± 3.6 0.3 ± 0.1* 0.04 ± 0.00 2.0 ± 0.2 ** 0.1 ± 0.0 0.05 ± 0.01** 
 
Statistical significance of differences: * p < 0.05; ** p < 0.01. 
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Crystal structures of LipA in complex with the Rc and Sc inhibitors  
The active site of B. subtilis LipA is solvent exposed, because no lid is present. It is located 
at the bottom of a small cleft between two loops consisting of residues 10 to 15 and 131 to 
137. In the crystal the active sites are exposed to a solvent channel as well. From the 
electron density maps it was clear that the IPG phosphonate inhibitors (scheme 2C) bound 
to both LipA molecules in the asymmetric unit (molecules A and B). After refinement, the 
electron density for the inhibitors bound in the active site is well defined in one molecule of 
the asymmetric unit but slightly less defined in the other molecule (figure 4). Residues 12-
16 in molecule B change conformation upon binding of the Sc or Rc inhibitor. In the 
unbound form, this loop partly closed the active site, but when the inhibitors are bound, it 





Figure 4: Final 2Fo-Fc electron density (contoured at 1 σ) of covalently bound inhibitors at S77. A) 
Rc inhibitor in molecule A. B) Rc inhibitor in molecule B. C) Sc inhibitor in molecule A. D) Sc 
inhibitor in molecule B. 
 
The Rc and Sc inhibitors are enantiopure at the chiral carbon atom of the IPG group, but 
they are racemic at the phosphorous atom (Rp or Sp). However, the structures of the 
complexes show that in both cases only one phosphorous enantiomer (Sp) is observed. It is 
generally assumed that the mechanism of phosphonate inhibition by serine hydrolases 
occurs via an in-line displacement reaction, resulting in an inversion of the configuration of 
the phosphorous atom. Since the priorities of the substituents at the phosphorous atom, as 
defined by Cahn et al, change during this nucleophilic displacement and the enzyme-
inhibitor complex has the Sp conformation, the fast-reacting inhibitor must have been the 
Sp enantiomer 222. 
 
The Sc and Rc inhibitors are bound in a similar way in a hydrophobic groove on the LipA 
surface (figure 5). As anticipated, one oxygen atom of the phosphonate group is hydrogen 
bonded to the two backbone amides in the oxyanion hole. No hydrogen bond interactions 
exist between the rest of the inhibitor and the protein. It is remarkable that in both 
enantiomers the oxygen atom between the IPG group and the phosphonate does not form a 
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hydrogen bond with H156. This hydrogen bond would be expected to be present in a true 
tetrahedral reaction intermediate of fatty acid ester hydrolysis 29.  
Nevertheless, the broader electron densities in this part of the inhibitors indicate some 
flexibility of the oxygen atom, suggesting such a hydrogen bond with H156 is possible part 
of the time. Both enantiomers have good Van-der-Waals contacts with the protein, with 
mainly hydrophobic residues. The solvent accessible surface of LipA decreases with very 
similar values upon binding of the Sc (197 Å2) or Rc inhibitor (204 Å2). The lack of clear 
enantioselectivity of B. subtilis LipA is understandable from the structures, since there are 
no specific interactions of the protein with the covalently bound transition state mimics and 




Figure 5: Stereoview of the environment of the covalently bound Rc inhibitor (A) and Sc inhibitor (B) 
to LipA. Surface representation of LipA with the Rc inhibitor (C) and Sc inhibitor (D) in the 




In this study, we have described a novel method for the directed evolution of 
enantioselective lipases. This principle is based on the combination of phage display 
technology and a selection step using enantiomeric phosphonate inhibitors. The relationship 
between the 3D structure and the enantioselectivity towards the substrate of interest, in our 
case IPG, can be studied in detail, since we have successfully elucidated the crystal 
structure of B. subtilis LipA with covalently bound enantiomeric phosphonate inhibitors. 
In the past years, several methods for the directed evolution of hydrolases have been 
introduced, but most of them were based on high-throughput screening and not on selection 
189,223-229. 
 
For probing large libraries, selection of improved variants is a prerequisite and phage 
display has been proposed to select catalysts with improved or novel activities. The use of 
transition state analogues 230, substrates anchored to the phage 104,231-233 or suicide inhibitors 
234-237 has been reported. To select variants with an inverted enantioselectivity for the 
production of enantiopure IPG, we employed the phage display technique with phosphonate 
suicide inhibitors, since phosphonates mimic the first transition state in ester hydrolysis 238-
241. We showed previously that a SIRAN immobilised phosphonate inhibitor is capable of 
an irreversible inactivation of B. subtilis LipA 103,217. Separate coupling of this racemic 
phosphonate inhibitor to both enantiomers of IPG resulted in (+)- and (-)-forms of the IPG 
phosphonate inhibitor (SIRAN Sc and Rc inhibitor, respectively). Thus, the selection 
method presented in this study is based on covalent attachment of a lipase substrate 
analogue to the active site of the displayed variants of B. subtilis LipA.  
 
Here, we introduce a novel sequential incubation method using both enantiomers of this 
suicide inhibitor, a so-called dual selection method, to firstly counterselect phages on a 
phosphonate inhibitor coupled to the undesired enantiomer of IPG (SIRAN Rc inhibitor) 
followed by a positive selection on the phosphonate linked to the desired enantiomer 
(SIRAN Sc inhibitor). We have investigated the feasibility of this phage display selection 
by constructing a B. subtilis LipA library randomised in a region flanking the active site 
(amino acid 16-20 of the mature LipA). One of the residues within this region, N18, has 
been suggested to be of particular interest for the enantioselective properties of this enzyme 
27,242,243.  
 
After 4 rounds of selection 15 mutants were characterised in detail. Strikingly, 11 mutants 
with enantioselectivity ratios comparable to the wild type LipA were retrieved. DNA 
sequencing revealed that a strong selection for wild type amino acids was observed. 
Interestingly, in 1 out of the 15 mutants a TGA termination codon was observed while a 
fully enzymatically active enzyme could still be isolated from the periplasm of those 
mutants. Indeed western blot analysis revealed the presence of a fully intact lipase (data not 
shown). A possible explanation for this phenomenon was provided by the fact that the TGA 
stop codon is not fully suppressed in this strain. Correspondingly, it is known that 
tryptophan is inserted at the UGA (opal) stop codon in some E. coli strains, resulting in an 
intact protein 244,245. To test this hypothesis, we have constructed the LipA F17DF19W 
mutant, which contained the UGG codon (tryptophan) instead of UGA codon (stop codon). 
After isolation of the periplasmic fraction of this mutant, the enantioselectivity towards IPG 
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butyrate was determined. In fact, this mutant had an enantiomeric excess ee of +2.13% at 
31% conversion. 
 
Besides the selection of variants with wild type like activities, we could demonstrate for 2 
mutants that an N18I mutation accounted for inversion of the enantioselectivity towards 
IPG. Interestingly, comparison of the Michaelis-Menten kinetics of the LipA N18I mutant 
with wild type LipA revealed that the kcat value of LipA N18I on the butyrate ester of (-)-
IPG was significantly reduced, while the Km value of LipA N18I towards the (+)-IPG ester 
was significantly lowered. As a consequence, LipA N18I possesses an improved catalytic 
efficiency towards the (+)-IPG ester. Upon hydrolysis of this ester, the enantiomer of 
interest (+)-IPG is formed.  
 
Comparison of the enantiomeric excess ee towards the IPG butyrate ester revealed an 
inversion of the enantioselectivity of LipA N18I as compared to LipA (ee value for LipA 
N18I = +32.9% and +35.3%; ee value for LipA = -33.3%). Although the changes in ee 
value are significant and encouraging, for practical applications the observed ee’s are still 
rather low. Several explanations can be given for the modest increase of the 
enantioselectivity: 
A) The library size spanning residues 16-20 is rather limited and mutation N18I simply is 
the best single mutant in this library. B) Catalytic activity does not solely depend on 
binding of the enzyme to the substrate, but also on completion of the catalytic cycle. C) The 
chiral carbon atom in IPG is relatively far from the actual site of catalysis in the enzyme. 
Moreover the (-)-IPG and (+)-IPG used for selection are stereochemically not very different 
and therefore the creation of a highly enantioselective enzyme may require more rigorous 
modification of the enzyme such as insertion of amino acids. 
 
With respect to B) one may wonder whether selection for strong binding could lead to the 
selection of inactive enzymes with impaired dissociation of the substrate. These mutants 
would still pass the selection process since the phages are rescued from the SIRAN beads 
by cleavage of the collagenase site leaving the immobilised enzyme behind. Within the 
group of selected mutants there was, however, no accumulation of inactive enzymes, which 
implies that this is not a major hurdle in the procedure. An important prerequisite for 
selection on phage is the formation of correctly folded enzymes. In fact, Danielsen et al 
have recently shown that the lipase from T. lanuginosa could be displayed on phages as a 
fusion to the phage coat protein g3p, but subsequent selection of improved lipase variants 
on suicide inhibitors failed 235. They suggest that the complex process of folding and 
secretion of lipases complicates the expression in a heterologous host. In addition, the 
activity of T. lanuginosa lipase is enhanced in the presence of lipid-water interfaces, 
complicating the design of a selection protocol. LipA of B. subtilis appears to be an 
important exception, as this enzyme does not require a chaperone for functional phage 
display. Another important advantage of this lipase is the lack of a lid, enabling the 
characterisation of the enzyme by Michaelis-Menten kinetics. The results obtained in this 
study clearly demonstrate that the selected LipA mutants were fully catalytically active and 
therefore correctly folded.  
 
With respect to C) an explanation is found in the 3D structure of the covalent B. subtilis 
lipase-inhibitor complex, which illustrates that the active site cleft of LipA can 
accommodate both IPG enantiomers equally well, and that both enantiomers have very 
similar binding modes. This explains that only a slight enantiopreference is observed. By 
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replacing the side chain of N18 by an isoleucine side chain several rotamers of isoleucine 
are possible. Each of these rotamers will have a too close Van-der-Waals contact with 
neighbouring amino acids (L160 (~2.3 Å) and A15 (~2.8 Å) or with H10 (~2.7 Å) and F19 
(~3.2 Å) depending on the rotamer conformation), since an isoleucine has an additional 
branch on the Cβ atom compared to asparagine. Therefore, small local rearrangements have 
to occur to make space for I18, but the exact outcome is hard to predict. Thus, more 
rigorous mutations may have to be constructed to evolve LipA of B. subtilis as a highly 
enantioselective enzyme for the kinetic resolution of IPG esters. Our outlook is therefore to 
focus on extending the amino acid region flanking the active site (amino acids 16-20 of 
mature LipA) using small stretches of amino acids. These stretches will be selected using 
the 3D structures of homologues of Bacillus LipA. Ideally, a lid-like structure will thus be 
formed covering the active site. Possibly, this could have a larger impact on the 
enantioselectivity of LipA. It is also thinkable that highly enantioselective LipA mutants 
can be obtained when a secondary alcohol instead of IPG (a primary alcohol) is present in 
the phosphonate inhibitor.  
 
In conclusion we have explored the feasibility to use phage display for the selection of an 
enantiospecific lipase. On the basis of the 3D structure of Bacillus LipA with bound IPG 
inhibitors the effect of the mutation has been explained. For further improvements of the 
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